JPMorgan reiterates Overweight rating on Regeneron stock ahead of Q2 earnings

JPMorgan has maintained an Overweight rating and $800 price target on Regeneron Pharmaceuticals (REGN), despite forecasting Q2 U.S. Eylea HD sales below consensus and highlighting continued Eylea franchise challenges. This is counterbalanced by significant recent FDA approvals for the blood cancer therapy Lynozyfic, projected by TD Cowen to reach $500 million annually by 2030, and an eighth U.S. indication for Dupixent. While JPMorgan noted a pipeline setback, the firm emphasizes the strength of Regeneron's diversified asset base and new therapeutic offerings, underpinning its positive long-term outlook.

Analysis

Regeneron Pharmaceuticals (REGN) faces a dichotomy of near-term headwinds for its established Eylea franchise against significant long-term growth from recent pipeline successes. JPMorgan, while maintaining an Overweight rating and an $800 price target, projects second-quarter Eylea sales below consensus, with Eylea 2mg sales forecast at $729 million (a 15% sequential decline) and Eylea HD at $315 million, citing ongoing patient affordability issues and competitive pressures. This bearish view on a key revenue driver is counterbalanced by major regulatory victories. The FDA's approval of Lynozyfic, a blood cancer therapy, is a notable catalyst; the drug showed a 70% objective response rate in trials, and TD Cowen projects it could capture $500 million in annual sales by 2030. Furthermore, Dupixent, in partnership with Sanofi, secured its eighth U.S. indication, reinforcing its status as a durable growth asset. The consensus among analysts, including TD Cowen's Buy rating and JPMorgan's maintained Overweight stance despite a noted pipeline setback, indicates that the long-term value of the diversified and expanding portfolio is seen as outweighing the immediate challenges impacting Eylea.

Key Decisions for Investors

• Investors should weigh the near-term revenue pressures on the Eylea franchise against the significant long-term growth potential from newly approved drugs like Lynozyfic and the expanding indications for Dupixent.
• Closely monitor the upcoming Q2 earnings report for Eylea sales figures, as performance relative to JPMorgan's sub-consensus forecast of $729 million for 2mg and $315 million for HD will be a key catalyst for the stock.
• Given the strong commercial potential of Lynozyfic, projected at $500 million in annual sales by 2030, and the wide analyst price target range of $504 to $940, long-term oriented investors might consider the current valuation an attractive entry point despite expected short-term volatility.